{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:39:31Z","timestamp":1770219571031,"version":"3.49.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.critrevonc.2009.01.003","type":"journal-article","created":{"date-parts":[[2009,2,24]],"date-time":"2009-02-24T16:35:51Z","timestamp":1235493351000},"page":"144-154","source":"Crossref","is-referenced-by-count":35,"title":["Strategies for minimizing complications of neutropenia: Prophylactic myeloid growth factors or antibiotics"],"prefix":"10.1016","volume":"72","author":[{"given":"John R.","family":"Wingard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Elmongy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"March (6)","key":"10.1016\/j.critrevonc.2009.01.003_bib1","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/339215","article-title":"Guidelines for the use of antimicrobial agents in neutropenic patients with cancer","volume":"34","author":"Hughes","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"February (2)","key":"10.1016\/j.critrevonc.2009.01.003_bib2","first-page":"122","article-title":"Prevention and treatment of cancer-related infections","volume":"6","author":"Segal","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"issue":"October (Suppl. 2)","key":"10.1016\/j.critrevonc.2009.01.003_bib3","first-page":"S17","article-title":"Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever","volume":"82","author":"Link","year":"2003","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.critrevonc.2009.01.003_bib4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1200\/JCO.2000.18.2.325","article-title":"Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system","volume":"18","author":"Voog","year":"2000","journal-title":"J Clin Oncol"},{"issue":"3\u20134","key":"10.1016\/j.critrevonc.2009.01.003_bib5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3109\/10428190009089435","article-title":"A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma","volume":"37","author":"Intragumtornchai","year":"2000","journal-title":"Leuk Lymphoma"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2009.01.003_bib6","first-page":"87a","article-title":"Predicting hematotoxicity in multicycle chemotherapy","volume":"94","author":"Kloess","year":"1999","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2009.01.003_bib7","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<796::AID-CNCR10>3.0.CO;2-P","article-title":"The predictive value of body protein for chemotherapy-induced toxicity","volume":"88","author":"Aslani","year":"2000","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2009.01.003_bib8","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1200\/JCO.1996.14.2.636","article-title":"Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia","volume":"14","author":"Blay","year":"1996","journal-title":"J Clin Oncol"},{"issue":"June\u2013July (6)","key":"10.1016\/j.critrevonc.2009.01.003_bib9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","article-title":"Risk models for predicting chemotherapy-induced neutropenia","volume":"10","author":"Lyman","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0002-9343(02)01036-7","article-title":"Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis","volume":"112","author":"Lyman","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib11","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib12","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1185\/030079907X219599","article-title":"Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials","volume":"23","author":"Pinto","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.critrevonc.2007.01.008","article-title":"Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel","volume":"63","author":"Gridelli","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib14","doi-asserted-by":"crossref","first-page":"979","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00008","article-title":"Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients","volume":"142","author":"Gafter-Gvili","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib15","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1056\/NEJMoa050078","article-title":"Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas","volume":"353","author":"Cullen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib16","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","author":"Bucaneve","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib17","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/cncr.22205","article-title":"Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions","volume":"107","author":"Leibovici","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib18","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJM199404283301717","article-title":"Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia","volume":"330","author":"Cometta","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/dkl425","article-title":"Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis","volume":"59","author":"Gafter-Gvili","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"October (1)","key":"10.1016\/j.critrevonc.2009.01.003_bib20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1365-2141.2001.03034.x","article-title":"Oral ciprofloxacin plus colistin: prophylaxis against bacterial infection in neutropenic patients A strategy for the prevention of emergence of antimicrobial resistance","volume":"115","author":"Prentice","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib21","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1200\/JCO.2006.08.7395","article-title":"Rational selection of patients for antibacterial prophylaxis after chemotherapy","volume":"25","author":"Cullen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"May (5)","key":"10.1016\/j.critrevonc.2009.01.003_bib22","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1200\/JCO.1994.12.5.1005","article-title":"Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support","volume":"12","author":"Gilbert","year":"1994","journal-title":"J Clin Oncol"},{"issue":"December (12)","key":"10.1016\/j.critrevonc.2009.01.003_bib23","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/BF01992162","article-title":"Strategy for antibiotic therapy in febrile neutropenic patients on selective antibiotic decontamination","volume":"12","author":"de Marie","year":"1993","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"April (4)","key":"10.1016\/j.critrevonc.2009.01.003_bib24","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/clinids\/20.4.907","article-title":"Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones","volume":"20","author":"Bow","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib25","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1200\/JCO.2007.13.8222","article-title":"Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia","volume":"26","author":"Elting","year":"2008","journal-title":"J Clin Oncol"},{"issue":"May (5)","key":"10.1016\/j.critrevonc.2009.01.003_bib26","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0002-9343(88)90062-9","article-title":"Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukaemia. The trade-off for reduced gram-negative sepsis","volume":"84","author":"Bow","year":"1988","journal-title":"Am J Med"},{"issue":"May (10)","key":"10.1016\/j.critrevonc.2009.01.003_bib27","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib28","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1200\/JCO.2004.00.7955","article-title":"Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study","volume":"23","author":"Timmer-Bonte","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib29","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2005.04.3281","article-title":"Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer","volume":"24","author":"Timmer-Bonte","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib30","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/annonc\/mdm438","article-title":"Pegfilgrastim +\/\u2212 ciprofloxacin for primary prophylaxis with TAC (docetaxel\/doxorubicin\/cyclophosphamide) chemotherapy for breast cancer Results from the GEPARTRIO study","volume":"19","author":"von Minckwitz","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib31","first-page":"472","article-title":"A prospective investigation of chemotherapy-induced neutropenia and quality of life","volume":"4","author":"Fortner","year":"2006","journal-title":"J Support Oncol"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib32","unstructured":"Infectious Diseases Society of Taiwan; Hematology Society of Taiwan; Medical Foundation in Memory Dr. Deh-Lin Cheng; Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education; CY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccine. Guidelines for the use of antimicrobial agents in patients with febrile neutropenia in Taiwan. J Microbiol Immunol Infect. 2005;38(Decmeber(6)):455\u20137."},{"issue":"July (Suppl. 1)","key":"10.1016\/j.critrevonc.2009.01.003_bib33","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1086\/383054","article-title":"Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary","volume":"39","author":"Masaoka","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"January","key":"10.1016\/j.critrevonc.2009.01.003_bib34","first-page":"53","article-title":"Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials","volume":"1","author":"Imran","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib35","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","article-title":"EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours","volume":"42","author":"Aapro","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib36","doi-asserted-by":"crossref","first-page":"188","DOI":"10.6004\/jnccn.2007.0019","article-title":"Myeloid growth factors, Clinical practice guidelines in oncology","volume":"5","author":"Crawford","year":"2007","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib37","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"issue":"March","key":"10.1016\/j.critrevonc.2009.01.003_bib38","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1200\/JCO.1998.16.3.1179","article-title":"Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis","volume":"3","author":"Engels","year":"1998","journal-title":"J Clin Oncol"},{"issue":"February","key":"10.1016\/j.critrevonc.2009.01.003_bib39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.6004\/jnccn.2008.0012","article-title":"Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice","volume":"2","author":"Crawford","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"issue":"August (16)","key":"10.1016\/j.critrevonc.2009.01.003_bib40","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jnci\/90.16.1205","article-title":"Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer The Cancer and Leukemia Group B","volume":"90","author":"Budman","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"June (6)","key":"10.1016\/j.critrevonc.2009.01.003_bib41","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.1990.8.6.963","article-title":"Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis","volume":"8","author":"Kwak","year":"1990","journal-title":"J Clin Oncol"},{"issue":"April (14)","key":"10.1016\/j.critrevonc.2009.01.003_bib42","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199504063321401","article-title":"Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up","volume":"6332","author":"Bonadonna","year":"1995","journal-title":"N Engl J Med"},{"issue":"September","key":"10.1016\/j.critrevonc.2009.01.003_bib43","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/oxfordjournals.annonc.a058619","article-title":"Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol The GELA. (Groupe d\u2019Etude des Lymphomes de l\u2019Adulte)","volume":"8","author":"Lepage","year":"1993","journal-title":"Ann Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2009.01.003_bib44","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0959-8049(99)00259-2","article-title":"Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer","volume":"36","author":"Chang","year":"2000","journal-title":"Eur J Cancer"},{"issue":"June (12)","key":"10.1016\/j.critrevonc.2009.01.003_bib45","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/1097-0142(20010615)91:12<2246::AID-CNCR1255>3.0.CO;2-4","article-title":"Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma","volume":"91","author":"Mayers","year":"2001","journal-title":"Cancer"},{"issue":"May (18)","key":"10.1016\/j.critrevonc.2009.01.003_bib46","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199405053301801","article-title":"Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma","volume":"330","author":"Wood","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib47","doi-asserted-by":"crossref","unstructured":"Bohlius J, Reiser M, Schwarzer G, et al. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma [Update of Cochrane Database Syst Rev. 2002]. Cochrane Database of Systematic Reviews CD003189; 2004.","DOI":"10.1002\/14651858.CD003189.pub2"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3816\/SCT.2003.n.002","article-title":"Epidemilogy of febrile neutropenia","volume":"1","author":"Lyman","year":"2003","journal-title":"Supportive Cancer Therapy"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib49","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00062752-200205000-00006","article-title":"Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients","volume":"9","author":"Lyman","year":"2002","journal-title":"Curr Opin Hematol"},{"issue":"February","key":"10.1016\/j.critrevonc.2009.01.003_bib50","doi-asserted-by":"crossref","first-page":"203","DOI":"10.6004\/jnccn.2007.0020","article-title":"Growth factors in leukemia","volume":"2","author":"Frankfurt","year":"2007","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib51","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2005.04.3281","article-title":"Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer","volume":"24","author":"Timmer-Bonte","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib52","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","article-title":"First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study","volume":"23","author":"Vogel","year":"2005","journal-title":"J Clin Oncol"},{"issue":"June","key":"10.1016\/j.critrevonc.2009.01.003_bib53","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/clinids\/14.6.1201","article-title":"Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors","volume":"6","author":"Elting","year":"1992","journal-title":"Clin Infect Dis"},{"issue":"October","key":"10.1016\/j.critrevonc.2009.01.003_bib54","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1046\/j.1365-2141.2003.04546.x","article-title":"Haemato-Oncology Task Force of the British Committee for Standards in Haematology Guidelines on the use of colony-stimulating factors in haematological malignancies","volume":"1","author":"Pagliuca","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib55","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer","volume":"325","author":"Crawford","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib56","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1200\/JCO.2007.13.0898","article-title":"Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy","volume":"26","author":"Timmer-Bonte","year":"2008","journal-title":"J Clin Oncol"},{"issue":"November","key":"10.1016\/j.critrevonc.2009.01.003_bib57","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0959-8049(98)00222-6","article-title":"The economics of febrile neutropenia: implications for the use of colony-stimulating factors","volume":"12","author":"Lyman","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib58","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1200\/jco.2006.24.18_suppl.8561","article-title":"Prospective validation of a risk model for first cycle neutropenic complications in patients receiving cancer chemotherapy","volume":"24","author":"Lyman","year":"2006","journal-title":"J Clin Oncol"},{"issue":"July","key":"10.1016\/j.critrevonc.2009.01.003_bib59","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1200\/JCO.1998.16.7.2392","article-title":"First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy","volume":"7","author":"Silber","year":"1998","journal-title":"J Clin Oncol"},{"issue":"November (22)","key":"10.1016\/j.critrevonc.2009.01.003_bib60","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1200\/JCO.2003.01.234","article-title":"Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients","volume":"1521","author":"Cruciani","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib61","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1023\/A:1012545507920","article-title":"Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study","volume":"12","author":"Tjan-Heijnen","year":"2001","journal-title":"Ann Oncol"},{"issue":"December (12)","key":"10.1016\/j.critrevonc.2009.01.003_bib62","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1080\/1042819031000119262","article-title":"OPPS Working Group; ANC Study Group Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy","volume":"44","author":"Lyman","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"August (8)","key":"10.1016\/j.critrevonc.2009.01.003_bib63","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1469-0691.1999.tb00175.x","article-title":"Molecular typing of fluoroquinolone-resistant and fluoroquinolone-susceptible Escherichia coli isolated from blood of neutropenic cancer patients in a single center","volume":"5","author":"Tascini","year":"1999","journal-title":"Clin Microbiol Infect"},{"issue":"April (8)","key":"10.1016\/j.critrevonc.2009.01.003_bib64","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1086\/428732","article-title":"Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies","volume":"40","author":"Reuter","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib65","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.urology.2007.02.035","article-title":"Granulocyte Colony-Stimulating Factor\/Granulocyte Colony-Stimulating Factor Receptor Biological Axis Promotes Survival and Growth of Bladder Cancer Cells","volume":"69","author":"Arup","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib66","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/cncr.22964","article-title":"Expression of Granulocyte-Colony-Stimulating Factor and Its Receptor in Human Ewing Sarcoma Cells and Patient Tumor Specimens: Potential Consequences of Granulocyte-Colony-Stimulating Factor Administration","volume":"110","author":"Morales-Arias","year":"2007","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2009.01.003_bib67","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1515\/CCLM.2004.253","article-title":"Hematopoietic cytokines as tumor markers","volume":"42","author":"Mroczko","year":"2004","journal-title":"Clin Chem Lab Med"},{"issue":"16","key":"10.1016\/j.critrevonc.2009.01.003_bib68","doi-asserted-by":"crossref","first-page":"8026","DOI":"10.1158\/0008-5472.CAN-06-0158","article-title":"Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo","volume":"66","author":"Gutschalk","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib69","first-page":"955","article-title":"Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on lung cancer: Roles of cyclooxygenase-2","volume":"17","author":"Uemura","year":"2007","journal-title":"Oncol Rep"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib70","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/jnci\/djk028","article-title":"Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy","volume":"99","author":"Hershman","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.critrevonc.2009.01.003_bib71","doi-asserted-by":"crossref","first-page":"337","DOI":"10.18553\/jmcp.2007.13.4.337","article-title":"Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices","volume":"13","author":"Morrison","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib72","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.6580","article-title":"Risk of hospitalization with Pegfilgrastim versus filgrastim prophylaxis: A retrospective cohort study","volume":"26","author":"Weycker","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.critrevonc.2009.01.003_bib73","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1524-4733.2007.00242.x","article-title":"Economic Analysis of Prophylactic Pegfilgrastim in Adult Cancer Patients Receiving Chemotherapy","volume":"11","author":"Eldar-Lissai","year":"2008","journal-title":"Value in Health"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib74","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib75","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"2-weekly vs. 3-weekly CHOP with and without etoposide for patients >60 years of age with aggressive non-Hodgkin's lymphoma (NHL): results of the NHL-B-2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib76","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","article-title":"2-weekly vs. 3-weekly CHOP with and without etoposide in young patients with good prognosis (low LDH) aggressive non-Hodgkin's lymphoma: results of the NHL-B-1 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib77","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood-2006-07-035709","article-title":"Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)","volume":"109","author":"Verdonck","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib78","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","volume":"19","author":"Sternberg","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2009.01.003_bib79","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","article-title":"Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours","volume":"42","author":"Sternberg","year":"2006","journal-title":"Euro J Cancer"},{"issue":"November (11)","key":"10.1016\/j.critrevonc.2009.01.003_bib80","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1097\/CCM.0b013e31818bdea3","article-title":"Meta-analysis under the spotlight: we must differentiate its limitations versus its prejudices","volume":"36","author":"Kalil","year":"2008","journal-title":"Crit Care Med"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842809000055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842809000055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T07:46:12Z","timestamp":1633160772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842809000055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S1040842809000055"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2009.01.003","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}